| Literature DB >> 30961357 |
Ajaikumar B Kunnumakkara1, Devivasha Bordoloi1, Bethsebie Lalduhsaki Sailo1, Nand Kishor Roy1, Krishan Kumar Thakur1, Kishore Banik1, Mehdi Shakibaei2, Subash C Gupta3, Bharat B Aggarwal4.
Abstract
IMPACT STATEMENT: The success rate for cancer drugs which enter into phase 1 clinical trials is utterly less. Why the vast majority of drugs fail is not understood but suggests that pre-clinical studies are not adequate for human diseases. In 1975, as per the Tufts Center for the Study of Drug Development, pharmaceutical industries expended 100 million dollars for research and development of the average FDA approved drug. By 2005, this figure had more than quadrupled, to $1.3 billion. In order to recover their high and risky investment cost, pharmaceutical companies charge more for their products. However, there exists no correlation between drug development cost and actual sale of the drug. This high drug development cost could be due to the reason that all patients might not respond to the drug. Hence, a given drug has to be tested in large number of patients to show drug benefits and obtain significant results.Entities:
Keywords: Cancer; clinical; cost; drugs; patient survival; pre-clinical
Mesh：
Substances：
Year: 2019 PMID： 30961357 PMCID： PMC6552400 DOI： 10.1177/1535370219839163
Source DB: PubMed Journal: Exp Biol Med (Maywood) ISSN： 1535-3699